EL SEVIER

Atherosclerosis 125 (1996) 275–277

atherosclerosis

Author index

Volume 125 (1996)

Akishita, M., Y. Ouchi, H. Miyoshi, A. Orimo, K. Kozaki, M. Eto, M. Ishikawa, S. Kim, K. Toba, H. Orimo, Estrogen inhibits endothelin-1 production and *c-fos* gene expression in rat aorta **125**, 27
Alexandersen, P., J. Haarbo, C. Christiansen, The relationship of natural androgens to coronary heart disease in males: a review **125**, 1
Allison, B.A., J. Hamilton, Benzoporphyrin derivative decreases the binding of low density lipoprotein to the glycosaminoglycan chondroitin-6-sulfate in vitro **125**, 153
Arii, K., see Nakauchi, Y. **125**, 161
Ascaso, J.F., see Carmena, R. **125**, 243

Bader, G., see Kraft, H.G. **125**, 53
Baker, P.B., see Friedman, M.H. **125**, 183
Banai, S., see Golomb, G. **125**, 171
Bausserman, L., see Bostom, A.G. **125**, 91
Bergström, M., see Carmena, R. **125**, 243
Bertrand, P., see Chajara, A. **125**, 193
Blom, H.J., see Franken, D.G. **125**, 71
Boers, G.H.J., see Franken, D.G. **125**, 71
Bostom, A.G., D. Shemin, K.L. Lapane, P. Sutherland, M.R. Nadeau, P.W.F. Wilson, D. Yoburn, L. Bausserman, G. Tofler, P.F. Jacques, J. Selhub, I.H. Rosenberg, Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study **125**, 91
Brack, M., see Samani, N.J. **125**, 209

Caldú, P., see Hurtado, I. **125**, 39
Camejo, G., see Carmena, R. **125**, 243
Cameron, J.D., see Dart, A.M. **125**, 145
Carmena, R., J.F. Ascaso, G. Camejo, G. Varela, E. Hurt-Camejo, J.M. Ordovas, J. Martinez-Valls, M. Bergström, B. Wallin, Effect of olive and sunflower oils on low density lipoprotein level, composition, size, oxidation and interaction with arterial proteoglycans **125**, 243
Chajara, A., H. Levesque, M.-N. Courel, C. Chauzy, C. Maingonnat, P. Bertrand, B. Delpech, Hyaluronan and hyaluronectin production in injured rat thoracic aorta **125**, 193
Chauhan, A., see Samani, N.J. **125**, 209
Chauzy, C., see Chajara, A. **125**, 193
Christiansen, C., see Alexandersen, P. **125**, 1
Courel, M.-N., see Chajara, A. **125**, 193
Cramb, R., see Rajman, I. **125**, 231
Cruysberg, J.R.M., see Franken, D.G. **125**, 71
Cullen, J., see Samani, N.J. **125**, 209
Cuniberti, L.A., see Werba, J.P. **125**, 257

Dart, A.M., X.L. Qi, J.D. Cameron, In vivo determinants of arterial stiffness **125**, 145
Day, I.N.M., see Talmud, P.J. **125**, 135
de Bono, D.P., see Samani, N.J. **125**, 209
Delpech, B., see Chajara, A. **125**, 193
Ding, Z., see Friedman, M.H. **125**, 183

Elinder, L.S., see Regnström, J. **125**, 217
Elisaf, M.C., see Karabina, S.-A.P. **125**, 121
Eto, M., see Akishita, M. **125**, 27

Fellermann, K., see Reimann, F.M. **125**, 63
Fiol, C., see Hurtado, I. **125**, 39
Fishbein, I., see Golomb, G. **125**, 171
Foo, J.I., see Mamotte, C.D.S. **125**, 103
Franken, D.G., G.H.J. Boers, H.J. Blom, J.R.M. Cruysberg, F.J.M. Trijbels, B.C.J. Hamel, Prevalence of familial mild hyperhomocysteinemia **125**, 71
Friedman, M.H., P.B. Baker, Z. Ding, B.D. Kuban, Relationship between the geometry and quantitative morphology of the left anterior descending coronary artery **125**, 183

Gammage, M.D., see Rajman, I. **125**, 231
Garg, U., see Tsai, M.Y. **125**, 267
Gaw, A., Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? **125**, 267

Gazit, A., see Golomb, G. **125**, 171
Gaffney, D., see Talmud, P.J. **125**, 135
Gershlick, A.H., see Samani, N.J. **125**, 209
Gertz, S.D., see Golomb, G. **125**, 171
Golomb, G., I. Fishbein, S. Banai, D. Mishaly, D. Moscovitz, S.D. Gertz, A. Gazit, E. Poradosu, A. Levitzki, Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model **125**, 171
Gosling, R.G., see Lehmann, E.D. **125**, 139
Goudevenos, J., see Karabina, S.-A.P. **125**, 121
Gracia, V., see Hurtado, I. **125**, 39

Haarbo, J., see Alexandersen, P. **125**, 1
Hamashige, N., see Nakauchi, Y. **125**, 161
Hamel, B.C.J., see Franken, D.G. **125**, 71
Hamilton, J., see Allison, B.A. **125**, 153
Hanson, N.Q., see Tsai, M.Y. **125**, 267
Harley, A., see Samani, N.J. **125**, 209
Hashimoto, K., see Nakauchi, Y. **125**, 161
Hatzistamou, J., see Kiaris, H. **125**, 47
Heath, K., see Talmud, P.J. **125**, 135
Higashi, T., see Sato, Y. **125**, 15
Holder, R.L., see Rajman, I. **125**, 231
Holme, I., see Regnström, J. **125**, 217
Hopkins, K.D., see Lehmann, E.D. **125**, 139
Horiuchi, S., see Sato, Y. **125**, 15
Humphries, S.E., see Talmud, P.J. **125**, 135
Hurt-Camejo, E., see Carmena, R. **125**, 243
Hurtado, I., C. Fiol, V. Gracia, P. Caldú, In vitro oxidised HDL exerts a cytotoxic effect on macrophages **125**, 39

Ishikawa, M., see Akishita, M. **125**, 27

Jacques, P.F., see Bostom, A.G. **125**, 91
Johansson, J., see Regnström, J. **125**, 217

Karabina, S.-A.P., M.C. Elisaf, J. Goudevenos, K.C. Siamopoulos, D. Sideris, A.D. Tselepis, PAF-acetylhydrolase activity on Lp(a) before and during Cu^{2+}-induced oxidative modification in vitro **125**, 121
Kendall, M.J., see Rajman, I. **125**, 231
Key, N.S., see Tsai, M.Y. **125**, 267
Kiaris, H., J. Hatzistamou, D.A. Spandidos, Instability at the H-*ras* minisatellite in human atherosclerotic plaques **125**, 47
Kim, S., see Akishita, M. **125**, 27
Kobori, S., see Sato, Y. **125**, 15
Kostner, G.M., see Kraft, H.G. **125**, 53
Kotze, M.J., see Langenhoven, E. **125**, 111
Kozaki, K., see Akishita, M. **125**, 27
Kraft, H.G., A. Lingenhel, G. Bader, G.M. Kostner, G. Utermann, The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes **125**, 53
Kuban, B.D., see Friedman, M.H. **125**, 183
Kumon, Y., see Nakauchi, Y. **125**, 161

Laguens, R.P., see Werba, J.P. **125**, 257
Langenhoven, E., L. Warnich, R. Thiart, D.C. Rubinsztein, D.R.v.d. Westhuyzen, A.D. Marais, M.J. Kotze, Two novel point mutations causing receptor-negative familial hypercholesterolemia in a South African Indian homozygote **125**, 111
Lapane, K.L., see Bostom, A.G. **125**, 91
Lehmann, E.D., K.D. Hopkins, R.G. Gosling, In vivo determinants of arterial stiffness **125**, 139
Lei, X., L. Maximilian Buja, Detection and localization of tumor necrosis factor-α in WHHL rabbit arteries **125**, 81
Levesque, H., see Chajara, A. **125**, 193
Levitzki, A., see Golomb, G. **125**, 171
Levy, R., see Werba, J.P. **125**, 257
Lingenhel, A., see Kraft, H.G. **125**, 53
Lodwick, D., see Samani, N.J. **125**, 209

Maingonnat, C., see Chajara, A. **125**, 193
Mamotte, C.D.S., M. Sturm, J.I. Foo, F.M. van Bockxmeer, R.R. Taylor, Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding **125**, 103
Marais, A.D., see Langenhoven, E. **125**, 111
Martin, D.S., see Samani, N.J. **125**, 209
Martinez-Valls, J., see Carmena, R. **125**, 243
Masnatta, L.D., see Werba, J.P. **125**, 257
Matsumura, T., see Sato, Y. **125**, 15
Maximilian Buja, L., see Lei, X. **125**, 81
Mishaly, D., see Golomb, G. **125**, 171
Miyazaki, A., see Sato, Y. **125**, 15
Miyoshi, H., see Akishita, M. **125**, 27
Morikawa, W., see Sato, Y. **125**, 15
Moscovitz, D., see Golomb, G. **125**, 171
Mölgaard, J., see Regnström, J. **125**, 217

Nadeau, M.R., see Bostom, A.G. **125**, 91
Nakauchi, Y., T. Suehiro, M. Yamamoto, N. Yasuoka, K. Arii, Y. Kumon, N. Hamashige, K. Hashimoto, Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease **125**, 161
Nilsson, J., see Regnström, J. **125**, 217
Nilsson, S., see Regnström, J. **125**, 217

Olsson, A.G., see Regnström, J. **125**, 217
Ordovas, J.M., see Carmena, R. **125**, 243
Orimo, A., see Akishita, M. **125**, 27
Orimo, H., see Akishita, M. **125**, 27
Ouchi, Y., see Akishita, M. **125**, 27

Pichel, R.H., see Werba, J.P. **125**, 257
Poradosu, E., see Golomb, G. **125**, 171

Qi, X.L., see Dart, A.M. **125**, 145

Rajman, I., M.J. Kendall, R. Cramb, R.L. Holder, M. Salih, M.D. Gammage, Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men **125**, 231

Regnström, J., G. Walldius, S. Nilsson, L.S. Elinder, J. Johansson, J. Mölgaard, I. Holme, A.G. Olsson, J. Nilsson, The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis **125**, 217
Reimann, F.M., F. Winkelmann, K. Fellermann, E.F. Stange, Reduced cholesterol esterification in CaCo-2 cells by indirect action of pravastatin **125**, 63
Rey, R.H., see Werba, J.P. **125**, 257
Rosenberg, I.H., see Bostom, A.G. **125**, 91
Rubinsztein, D.C., see Langenhoven, E. **125**, 111

Sakai, M., see Sato, Y. **125**, 15
Salih, M., see Rajman, I. **125**, 231
Samani, N.J., D.S. Martin, M. Brack, J. Cullen, R. Wallis, D. Lodwick, A. Chauhan, A. Harley, J.R. Thompson, A.H. Gershlick, D.P. de Bono, Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty **125**, 209
Sato, Y., S. Kobori, M. Sakai, T. Yano, T. Higashi, T. Matsumura, W. Morikawa, T. Terano, A. Miyazaki, S. Horiuchi, M. Shichiri, Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-β activation **125**, 15
Schwichtenberg, K., see Tsai, M.Y. **125**, 267
Selhub, J., see Bostom, A.G. **125**, 91
Shemin, D., see Bostom, A.G. **125**, 91
Shichiri, M., see Sato, Y. **125**, 15
Siamopoulos, K.C., see Karabina, S.-A.P. **125**, 121
Sideris, D., see Karabina, S.-A.P. **125**, 121
Spandidos, D.A., see Kiaris, H. **125**, 47
Stange, E.F., see Reimann, F.M. **125**, 63
Sturm, M., see Mamotte, C.D.S. **125**, 103
Suehiro, T., see Nakauchi, Y. **125**, 161
Suh, A., see Tsai, M.Y. **125**, 267
Sutherland, P., see Bostom, A.G. **125**, 91

Talmud, P.J., O.J. Tamplin, K. Heath, D. Gaffney, I.N.M. Day, S.E. Humphries, Rapid testing for three mutations causing familial defective apolipoprotein B100 in 562 patients with familial hypercholesterolaemia **125**, 135
Tamplin, O.J., see Talmud, P.J. **125**, 135
Taylor, R.R., see Mamotte, C.D.S. **125**, 103
Terano, T., see Sato, Y. **125**, 15
Thiart, R., see Langenhoven, E. **125**, 111
Thompson, J.R., see Samani, N.J. **125**, 209
Toba, K., see Akishita, M. **125**, 27
Tofler, G., see Bostom, A.G. **125**, 91
Trijbels, F.J.M., see Franken, D.G. **125**, 71
Tsai, M.Y., U. Garg, N.S. Key, N.Q. Hanson, A. Suh, K. Schwichtenberg, Erratum to "Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria" [Atherosclerosis 122 (1996) 69][1] **125**, 267
Tselepis, A.D., see Karabina, S.-A.P. **125**, 121

Utermann, G., see Kraft, H.G. **125**, 53

van Bockxmeer, F.M., see Mamotte, C.D.S. **125**, 103
Varela, G., see Carmena, R. **125**, 243

Walldius, G., see Regnström, J. **125**, 217
Wallin, B., see Carmena, R. **125**, 243
Wallis, R., see Samani, N.J. **125**, 209
Warnich, L., see Langenhoven, E. **125**, 111
Werba, J.P., L.A. Cuniberti, R.P. Laguens, L.D. Masnatta, R.H. Rey, R. Levy, R.H. Pichel, Injury produces early rise in lipoprotein lipase activity in rabbit aorta **125**, 257
Westhuyzen, D.R.v.d., see Langenhoven, E. **125**, 111
Wilson, P.W.F., see Bostom, A.G. **125**, 91
Winkelmann, F., see Reimann, F.M. **125**, 63

Yamamoto, M., see Nakauchi, Y. **125**, 161
Yano, T., see Sato, Y. **125**, 15
Yasuoka, N., see Nakauchi, Y. **125**, 161
Yoburn, D., see Bostom, A.G. **125**, 91

ELSEVIER

Atherosclerosis 125 (1996) 279–280

atherosclerosis

Subject index

Volume 125 (1996)

Acyl-CoA cholesteryl acyltransferase **125**, 63
Androgens **125**, 1
Angiography **125**, 183
Angiotensin-converting enzyme **125**, 209
Angiotensin I-converting enzyme **125**, 161
Angiotensin II type 1 receptor **125**, 161
Animal model **125**, 257
Aorta **125**, 193
Apo(a) **125**, 53
Apo(a) isoform **125**, 121
apoB Mutation testing **125**, 135
Apolipoprotein(a) **125**, 15
Apolipoprotein E **125**, 209
Arterial distensibility **125**, 139
Arteriosclerosis **125**, 91
Atherosclerosis **125**, 27, 39, 47, 257
Atherosis **125**, 139

Benzoporphyrin derivative **125**, 153

CaCo-2 cell **125**, 63
c-*fos* **125**, 27
Cholesterol **125**, 63
Cholestyramine **125**, 217
Chondroitin-6-sulfate **125**, 153
Compliance **125**, 139
Controlled release **125**, 171
Coronary angiography **125**, 161
Coronary artery **125**, 183
Coronary artery disease **125**, 231
Coronary heart disease **125**, 1
Cytotoxicity **125**, 39

Diets **125**, 243
DNA diagnosis **125**, 111
Drug implants **125**, 171

Endothelin **125**, 27
End-stage renal disease **125**, 91
Estrogen **125**, 27
Familial **125**, 71
Familial defective apoB100 **125**, 135
Familial defective apolipoprotein B-100 **125**, 103
Familial hypercholesterolaemia **125**, 135
Fibrinogen **125**, 91

Genes **125**, 209
Genetic instability **125**, 47

High density lipoprotein **125**, 217
Histomorphology **125**, 183
HMG-CoA reductase inhibitor **125**, 63
HMGCoA reductase inhibitors **125**, 103
Homocysteine **125**, 91
H-*ras* **125**, 47
Human atherosclerosis **125**, 217
Hyaluronan **125**, 193
Hyaluronectin **125**, 193
Hyperhomocysteinemia **125**, 71

Immunocytochemistry **125**, 81
Implantable drug delivery system **125**, 171
Initiation codon mutation **125**, 111
Injury **125**, 193
In situ transcription **125**, 81
Intimal proliferation **125**, 257

Lag phase **125**, 39
LDL **125**, 63
LDL affinity to proteoglycans **125**, 243
LDL β carotene **125**, 243
LDL oxidation **125**, 243
LDL-receptor **125**, 103
LDL retinol **125**, 243
LDL size **125**, 243
LDL subfractions **125**, 231
LDL α-tocopherol **125**, 243
Lipids **125**, 139
Lipid-soluble vitamins **125**, 217
Lipoprotein(a) **125**, 15
Lipoprotein (a) **125**, 121

Lipoprotein lipase **125**, 257
Low density lipoprotein **125**, 153, 217
Low density lipoprotein receptor **125**, 111
Lp(a) **125**, 91
Lysophosphatidylcholine **125**, 121

Macrophage growth **125**, 15
Macrophages **125**, 39
Males **125**, 1
Minisatellite **125**, 47

Olive oil **125**, 243
Oxidation **125**, 121, 217
Oxidised HDL **125**, 39
Oxidised LDL **125**, 39

PAF-acetylhydrolase **125**, 121
PFGE **125**, 53
Phenotyping **125**, 53
Photodynamic therapy **125**, 153
Polymerase chain reaction **125**, 111
Polymorphism **125**, 53, 161
Pravastatin **125**, 63
Probucol **125**, 217
Protein tyrosine kinase **125**, 171
PTCA **125**, 209
Pulse wave velocity **125**, 139

Quantitative arteriography **125**, 217

Rat **125**, 193
Restenosis **125**, 171, 209

Sclerosis **125**, 139
SDS electrophoresis **125**, 53
Simvastatin **125**, 103
Smooth muscle cell **125**, 27
Stiffness **125**, 139
Sunflower oil **125**, 243
Susceptibility **125**, 39

Tetrazolium salts **125**, 63
TGF-β **125**, 15
TNF-α mRNA **125**, 81
Triglycerides **125**, 231
Tyrphostin **125**, 171

Vascular disease **125**, 71
Vascular geometry **125**, 183

WHHL rabbit **125**, 81